Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Teva Branded Pharmaceutical Products R&D, Inc.
With
United BioSource, LLC
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female
Age 12 years or greater at time of enrollment
Diagnosis of PAR for at least one year; and 2)a positive skin prick (ie, epicutaneous) or serum-specific IgE test within the past 2 years to a perennial allergen as appropriate for the location; and 3)PAR symptoms that are consistent with exposure to this allergen for at least one year
Uncontrolled rhinitis symptoms at the time of assessment as confirmed by a score of 21 or less on the RCAT
Newly prescribed BDP Nasal Aerosol (within the past 7 days but have not yet used)
Willing and able to complete surveys in English on a computer with internet access
Willing and able to provide informed consent prior to entering the study (or parent/caregiver/legal guardian if applicable)
You may not be if
Current acute or chronic sinusitis or chronic purulent nasal discharge
Rhinitis medicamentosa or nasal structural abnormalities (including nasal polyps and clinically significant septal deviation) that significantly interfere with nasal airflow
Acute upper respiratory infection within the past 14 days
Used any pressurized metered-dose inhaler INS product (including BDP Nasal Aerosol and Ciclesonide Nasal Aerosol) within the past 90 days
Used any experimental therapy for AR within the past 30 days
Any condition which the investigator feels may interfere with the study
Clareo Health | Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis
